基本説明
Chart the process of industrial chemical synthesis, from the first discovery of a molecule to its entry in the marketplace as a drug.
Full Description
Who wins the race to turn molecules into medicines? How much does it cost? What factors influence the choice of synthetic routes and reaction mechanisms? How can pharmaceutical companies protect their discoveries? In From Bench to Market, Walter Cabri and Romano Di Fabio chart the process of industrial chemical synthesis, from the first discovery of a molecule, or 'new chemical entity', to its entry in the marketplace as a drug. They discuss all aspects related to the process research for bulk production, including comparison between different synthetic routes, key methodologies and reaction mechanisms, costs, patent competition, and crystalline forms. The authors use the real chemical history of the development of drugs from several therapeutic areas as detailed case studies, each chosen to illustrate a range of issues and methodologies in industrial chemistry. Several chapters cover the development of the various ß-lactam antibiotics; two chapters describe the discovery and synthesis of the anticancer drugs Idarubicin and Paclitaxal; in another chapter, the synthesis of the anti-viral drug Acyclovir and the 'patent war' that resulted are explored. Between them, the authors represent considerable first-hand experience in pharmaceutical research and development. The technical, practical, and strategic information they have amassed make this essential reading for graduate and undergraduate chemists intending to work in the pharmaceutical industry, as well as for industrial chemists themselves. Lecturers teaching courses in medicinal and organic chemistry will also find it useful.
Contents
Preface ; 1. Process research and development: The modern approach ; 2. Non-classical ss-lactam antibiotics ; 3. Imipenem ; 4. Sanfetrinems ; 5. Ritipenems ; 6. Losartan ; 7. Nabumetone ; 8. Acyclovir ; 9. Idarubicin ; 10. Paclitaxel ; 11. The drug discovery process: Towards a new paradigm
